Technology
Health
Biotechnology

Jounce Therapeutics

$5.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (4.86%) Today
-$0.13 (-2.51%) After Hours

Why Robinhood?

You can buy or sell JNCE and other stocks, options, ETFs, and crypto commission-free!

About

Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Read More Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Employees
115
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
162.86M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
347.94K
High Today
$5.23
Low Today
$4.94
Open Price
$4.94
Volume
39.54K
52 Week High
$11.82
52 Week Low
$2.66

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2017 IPO
US

News

NasdaqMay 8

Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.06, delivering a surprise of 82.86%. Over the last four quarters, the compa...

33
Markets InsiderMay 8

Jounce Therapeutics Reports First Quarter 2019 Financial Results

- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patie...

13
Markets InsiderMay 1

Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019

43

Earnings

-$0.49
-$0.35
-$0.20
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.